Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND +2.89%11 Buyback Yield % is -37.87 as of Jul. 29, 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 735 Biotechnology companies, Vyome Holdings ranks worse than 79.46% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Vyome Holdings's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HIND vs CTXR, MBRX, AKTX: Buyback Yield % Comparison
For the Biotechnology subindustry, Vyome Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vyome Holdings (HIND) has a Buyback Yield % of -37.87 as of Jul. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Vyome Holdings and its competitors. According to the industry distribution chart, Vyome Holdings ranks #584 out of 735 companies in the Biotechnology industry, placing it in the top 79.5%.
Is Vyome Holdings' Buyback Yield % too high?
Vyome Holdings' current Buyback Yield % is -37.87. Based on the distribution chart, Vyome Holdings ranks #584 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' Buyback Yield % compare to CTXR and MBRX?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #584 out of 735 companies for Buyback Yield %. This places Vyome Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Vyome Holdings and its competitors. Vyome Holdings's current Buyback Yield % is -37.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current Buyback Yield % of -37.87. The current Buyback Yield % is -37.87. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Vyome Holdings (HIND), the current Buyback Yield % is -37.87 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
